171 related articles for article (PubMed ID: 16808592)
1. Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.
Finlay JC; Zhu TC; Dimofte A; Stripp D; Malkowicz SB; Busch TM; Hahn SM
Photochem Photobiol; 2006; 82(5):1270-8. PubMed ID: 16808592
[TBL] [Abstract][Full Text] [Related]
2. Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.
Zhu TC; Dimofte A; Finlay JC; Stripp D; Busch T; Miles J; Whittington R; Malkowicz SB; Tochner Z; Glatstein E; Hahn SM
Photochem Photobiol; 2005; 81(1):96-105. PubMed ID: 15535736
[TBL] [Abstract][Full Text] [Related]
3. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.
Zhu TC; Finlay JC; Hahn SM
J Photochem Photobiol B; 2005 Jun; 79(3):231-41. PubMed ID: 15896650
[TBL] [Abstract][Full Text] [Related]
4. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM
J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729
[TBL] [Abstract][Full Text] [Related]
5.
Finlay JC; Zhu TC; Dimofte A; Stripp D; Malkowicz SB; Whittington R; Miles J; Glatstein E; Hahn SM
Proc SPIE Int Soc Opt Eng; 2014 Jun; 5315():132-142. PubMed ID: 26146442
[TBL] [Abstract][Full Text] [Related]
6. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates.
Solonenko M; Cheung R; Busch TM; Kachur A; Griffin GM; Vulcan T; Zhu TC; Wang HW; Hahn SM; Yodh AG
Phys Med Biol; 2002 Mar; 47(6):857-73. PubMed ID: 11936174
[TBL] [Abstract][Full Text] [Related]
7. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.
Yu G; Durduran T; Zhou C; Zhu TC; Finlay JC; Busch TM; Malkowicz SB; Hahn SM; Yodh AG
Photochem Photobiol; 2006; 82(5):1279-84. PubMed ID: 16696593
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
[TBL] [Abstract][Full Text] [Related]
9.
Finlay JC; Zhu TC; Dimofte A; Stripp D; Malkowicz SB; Whittington R; Miles J; Glatstein E; Hahn SM
Proc SPIE Int Soc Opt Eng; 2005 Apr; 5689():299-310. PubMed ID: 26136613
[TBL] [Abstract][Full Text] [Related]
10. In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy.
Zhu TC; Hahn SM; Kapatkin AS; Dimofte A; Rodriguez CE; Vulcan TG; Glatstein E; Hsi RA
Photochem Photobiol; 2003 Jan; 77(1):81-8. PubMed ID: 12856887
[TBL] [Abstract][Full Text] [Related]
11. Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm.
Altschuler MD; Zhu TC; Li J; Hahn SM
Med Phys; 2005 Dec; 32(12):3524-36. PubMed ID: 16475751
[TBL] [Abstract][Full Text] [Related]
12. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.
Dimofte A; Zhu TC; Hahn SM; Lustig RA
Lasers Surg Med; 2002; 31(5):305-12. PubMed ID: 12430147
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy in the canine prostate using motexafin lutetium.
Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
Du KL; Mick R; Busch TM; Zhu TC; Finlay JC; Yu G; Yodh AG; Malkowicz SB; Smith D; Whittington R; Stripp D; Hahn SM
Lasers Surg Med; 2006 Jun; 38(5):427-34. PubMed ID: 16788929
[TBL] [Abstract][Full Text] [Related]
15. In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system.
Kostenich G; Orenstein A; Roitman L; Malik Z; Ehrenberg B
J Photochem Photobiol B; 1997 May; 39(1):36-42. PubMed ID: 9210320
[TBL] [Abstract][Full Text] [Related]
16. Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.
Patel H; Mick R; Finlay J; Zhu TC; Rickter E; Cengel KA; Malkowicz SB; Hahn SM; Busch TM
Clin Cancer Res; 2008 Aug; 14(15):4869-76. PubMed ID: 18676760
[TBL] [Abstract][Full Text] [Related]
17. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
Kereiakes DJ; Szyniszewski AM; Wahr D; Herrmann HC; Simon DI; Rogers C; Kramer P; Shear W; Yeung AC; Shunk KA; Chou TM; Popma J; Fitzgerald P; Carroll TE; Forer D; Adelman DC
Circulation; 2003 Sep; 108(11):1310-5. PubMed ID: 12939212
[TBL] [Abstract][Full Text] [Related]
18. PDT dose dosimetry for Photofrin-mediated pleural photodynamic therapy (pPDT).
Ong YH; Kim MM; Finlay JC; Dimofte A; Singhal S; Glatstein E; Cengel KA; Zhu TC
Phys Med Biol; 2017 Dec; 63(1):015031. PubMed ID: 29106380
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium.
Chou TM; Woodburn KW; Cheong WF; Lacy SA; Sudhir K; Adelman DC; Wahr D
Catheter Cardiovasc Interv; 2002 Nov; 57(3):387-94. PubMed ID: 12410519
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells.
Chen Z; Woodburn KW; Shi C; Adelman DC; Rogers C; Simon DI
Arterioscler Thromb Vasc Biol; 2001 May; 21(5):759-64. PubMed ID: 11348871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
